Company / SG&A Expense
Rani Therapeutics Holdings, Inc. SG&A Expense History
FY2021-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest SG&A Expense
$23.9M
FY2025
5-year range
$5.0M / $27.8M
FY2021-FY2025
Trend
-9.6%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
Improved from $28M to $24M over the past 3 years.
Based on SEC 10-K filings.
$24M in FY2025 with a 3-year CAGR of -4.9%.
Improved from $28M to $24M over the past 3 years.
SG&A Expense over time
Growth rates
- 3-Year CAGR
- -4.9%
- 5-Year CAGR
- -
- 10-Year CAGR
- -
Key checks
Key Insights
- 3-year CAGR of -4.9%, indicating a declining trend.
- In FY2025, sg&a expense decreased 9.6% year-over-year.
Company context
Key Data Points
- Altman Z-Score -1.77 (distress zone, below 1.8 threshold)
- Low earnings quality (accrual-heavy earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | SG&A ExpenseValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $23.9M | -9.6% |
| FY2024 | $26.5M | -4.9% |
| FY2022 | $27.8M | +460.9% |
| FY2021 | $5.0M | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026